August 25, 2003
San Antonio Business Journal
San Antonio drug developer Ilex Oncology Inc. has announced that enrollment
in its global, multi-center Phase II trial of Campath for multiple sclerosis
has reached more than 95 people.
Ilex President and CEO Jeff Buchalter says that puts the company at the midpoint of its projected goals.
Separately, an independent data safety monitoring board overseeing the clinical trial has completed an interim review of the study and has recommended the study to continue.
"Our expectations are to finish trial enrollment by the end of 2003," Buchalter says. "While it is too early to draw any conclusions at this point, we are encouraged to see such rapid enrollment."
Ilex is investigating the effectiveness of Campath treating previously untreated patients with relapsing or remitting multiple sclerosis.
The Food and Drug Administration in 2001 already granted Ilex the right
to treat patients with B-cell chronic lymphocytic leukemia with Campath.
Copyright © 2003, American City Business Journals Inc.